Clinical Trial

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.
Protocol Amendment History 3 changes
notable Trial sites expanded: 7 -> 15 locations 2026-06-02
notable Trial sites expanded: 1 -> 4 locations 2026-04-14
critical Recruitment opened 2026-04-08
Trial Details
NCT Number NCT07405151
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: Daiichi Sankyo
Conditions Oesophageal Squamous Cell Carcinoma
Enrollment 60 participants
Start Date 2026-03-27
Primary Completion 2027-06-12 (estimated)
Study Completion 2028-06-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-30